Maxim analyst Jason McCarthy downgraded Neurotrope to Hold from Buy without a price target after the company’s Phase 2 study for lead candidate bryostatin in treatment of moderate-to-severe Alzheimer’s disease did not meet its primary endpoint. The stock in afternoon trading is down 80%, or $3.50, to 90c. The analyst, who notes Neurotrope ended Q2 with $21M in cash, says he’s awaiting clarity on if there is a path forward for brystatin.